FORANE LIQUID

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

ISOFLURANE

Доступна з:

BAXTER CORPORATION

Код атс:

N01AB06

ІПН (Міжнародна Ім'я):

ISOFLURANE

Дозування:

100%

Фармацевтична форма:

LIQUID

Склад:

ISOFLURANE 100%

Адміністрація маршрут:

INHALATION

Одиниць в упаковці:

100 ML

Тип рецепту:

Prescription

Терапевтична области:

INHALATION ANESTHETICS

Огляд продуктів:

Active ingredient group (AIG) number: 0114368001; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

1999-12-31

Характеристики продукта

PRODUCT MONOGRAPH
PR
FORANE
(isoflurane, USP)
Liquid, 100% v/v
Inhalation Anesthetic
Baxter Corporation
Mississauga, Ontario
Canada L5N 0C2
Date of Revision:
January 30, 2018
Submission Control No.: 207201
Baxter and Forane are registered trademarks of Baxter International
Inc.
_ _
FORANE (isoflurane, USP) Product Monograph
Page 2 of 28
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE
REACTIONS....................................................................................................8
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE.................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
................................................................................19
PHARMACEUTICAL
INFORMATION..........................................................................19
DETAILED PHARMACOLOGY
.....................................................................................20
TOXICOLOGY
...........................................